Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care

Cellulitis Clinical Trial

— SSTIBE  

Official title:

Decreasing Antibiotic Duration for Skin and Soft Tissue Infections in Pediatric Primary Care Using Behavioral Economics Methods, A Cluster Randomized Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05226260
• Other study ID #: STUDY00001964
• Status: Active, not recruiting
• Phase: N/A
• Start date: November 1, 2021
• Est. completion date: March 1, 2024

Study information

• Verified date: September 2023
• Source: Nationwide Children's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study the efficacy of a package of behavioral economics strategies (versus an education-only control condition) in altering clinician behavior regarding antibiotic prescription duration for skin and soft tissue infection (SSTI).

Description:

The investigators propose a prospective, cluster randomized trial of Epic order panels in the 14 Nationwide Children's Hospital (NCH) primary care clinics. Investigators have designed user-friendly Epic order panels from which providers may select guideline concordant antibiotics by simply typing in a diagnosis (cellulitis) or antibiotic name. These order panels are prepopulated with the default, short-course (guideline-concordant) antibiotic duration, saving clinicians several clicks within the electronic medical record (EMR). If a provider changes the prescribed duration from the one defaulted, a free text box will appear for them to write an acknowledgement reason (accountable justification). All 14 clinics will receive baseline education (control condition) about common infections and local and national guidelines for antibiotic choice and duration of treatment. Clinician prescribers will also be instructed about the presence of a basic order panel. The full functionality of the default [short/desired] duration order panel will only be released to intervention clinics. The order panels will be restricted in Epic to clinics randomized to the intervention. The investigators hypothesize that clinics with the intervention will have higher rates of short course antibiotics for SSTI versus control clinics.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 98
• Est. completion date: March 1, 2024
• Est. primary completion date: March 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 3 Months to 99 Years

Eligibility

Inclusion Criteria:

• diagnosis codes A46 (cellulitis), L03 (cellulitis and acute lymphangitis), J34 or L02 (abscess, furuncle), or L01 (impetigo) AND

• those who received a prescription for an enteral antibiotic

• patient's treated in Nationwide Children's Hospital primary care clinics

Exclusion Criteria:

• Patients less than 3 months of age

• Animal bite

• Human bite

• Foreign body

• Diagnosis of hidradenitis suppurativa

• Immunocompromising conditions (primary immune deficiency, chemotherapy, etc)

• burns

Related Conditions & MeSH terms

• Abscess
• Antibiotic Duration
• Behavioral Economics
• Cellulitis
• Communicable Diseases
• Drain Abscess
• Impetigo
• Infections
• Skin Diseases, Infectious
• Skin Infection
• Soft Tissue Infections

Intervention

Behavioral:
• Default Duration order Panel
The SSTI order panel will present itself when a provider types in either a drug name or diagnosis (cellulitis, impetigo, etc). Clinicians in control clinics will have access to a basic order panel which will include diagnosis and corresponding antibiotic of choice. Clinicians in intervention clinics will have access to order panels with the following additional components: prepopulated order duration fields that default to the recommended treatment duration.

Locations

Country	Name	City	State
United States	Nationwide Children's Hospital Primary Care Clinics	Columbus	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Nationwide Children's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of short antibiotics	Rates of long and short antibiotics will be analyzed on the clinic and provider level for both intervention and control groups	12 months